Naïm Bouazza

Summary

Country: France

Publications

  1. doi A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients
    Naïm Bouazza
    Universite Paris Descartes, Sorbonne Paris, France
    AIDS 27:761-8. 2013
  2. pmc Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Br J Clin Pharmacol 74:971-7. 2012
  3. pmc Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Unite de recherche clinique, Hôpital Tarnier, 89 rue d Assas, 75006 Paris, France
    Antimicrob Agents Chemother 54:3280-6. 2010
  4. pmc Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, France
    Orphanet J Rare Dis 6:86. 2011
  5. doi Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité France, Paris, France
    J Acquir Immune Defic Syndr 58:283-8. 2011
  6. pmc Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 55:3498-504. 2011
  7. pmc Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women
    Sihem Benaboud
    Université Paris Descartes Sorbonne Paris Cité, EA3620, Paris, France
    Antimicrob Agents Chemother 56:857-62. 2012
  8. pmc Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?
    Floris Fauchet
    EA 3620 Université Paris Descartes, Sorbonne Paris Cité, Paris, France Unité de Recherche Clinique, AP HP, Hôpital Tarnier, Paris, France
    Br J Clin Pharmacol 78:1387-96. 2014
  9. pmc Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children
    Floris Fauchet
    EA 3620 Université Paris Descartes, Sorbonne Paris Cité, Paris, France
    Antimicrob Agents Chemother 57:4801-8. 2013
  10. pmc Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women
    Sihem Benaboud
    Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 56:776-82. 2012

Detail Information

Publications16

  1. doi A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients
    Naïm Bouazza
    Universite Paris Descartes, Sorbonne Paris, France
    AIDS 27:761-8. 2013
    ....
  2. pmc Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Br J Clin Pharmacol 74:971-7. 2012
    ....
  3. pmc Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Unite de recherche clinique, Hôpital Tarnier, 89 rue d Assas, 75006 Paris, France
    Antimicrob Agents Chemother 54:3280-6. 2010
    ..h was obtained with a 10-mg/kg once-daily lamivudine (3TC) dose for children below 17 kg; the recommended dose of 8 mg/kg seems to be sufficient in children weighing more than 17 kg. These assumptions should be prospectively confirmed...
  4. pmc Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, France
    Orphanet J Rare Dis 6:86. 2011
    ..This study was aimed to describe the relationship between cysteamine plasma concentrations and white blood cell cystine levels, and to simulate an optimized administration scheme to improve the management of patients with cystinosis...
  5. doi Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité France, Paris, France
    J Acquir Immune Defic Syndr 58:283-8. 2011
    ..The main goal was then to suggest for the first time the dose of tenofovir disoproxil fumarate (TDF) to give in children...
  6. pmc Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents
    Naïm Bouazza
    EA 3620, Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 55:3498-504. 2011
    ....
  7. pmc Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women
    Sihem Benaboud
    Université Paris Descartes Sorbonne Paris Cité, EA3620, Paris, France
    Antimicrob Agents Chemother 56:857-62. 2012
    ....
  8. pmc Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?
    Floris Fauchet
    EA 3620 Université Paris Descartes, Sorbonne Paris Cité, Paris, France Unité de Recherche Clinique, AP HP, Hôpital Tarnier, Paris, France
    Br J Clin Pharmacol 78:1387-96. 2014
    ..The main goal of the study was to describe the pharmacokinetics of maternal zidovudine (ZDV) administration during pregnancy and labour and to evaluate their impact on fetal concentrations and exposures...
  9. pmc Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected children
    Floris Fauchet
    EA 3620 Université Paris Descartes, Sorbonne Paris Cité, Paris, France
    Antimicrob Agents Chemother 57:4801-8. 2013
    ..9 kg and from 300 to 250 mg BID for the WB from 30 to 39.9 kg. The highest dose, 300 mg BID, should be started from body weights of 40 kg. ..
  10. pmc Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women
    Sihem Benaboud
    Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 56:776-82. 2012
    ..9. Pregnant women had a 22% higher apparent clearance than nonpregnant and parturient women; however, this increase did not lead to subexposure and should not require a dosage adjustment...
  11. pmc Evaluation of effect of impaired renal function on lamivudine pharmacokinetics
    Naïm Bouazza
    EA 3620, Université Paris Descartes Sorbonne Paris Cité, Paris, France Unité de Recherche Clinique, AP HP, Hôpital Tarnier, Paris, France
    Br J Clin Pharmacol 78:847-54. 2014
    ..This study aimed to describe lamivudine pharmacokinetics in patients with impaired renal function and to evaluate the consistency of current dosing recommendations...
  12. doi Concentration-response model of lopinavir/ritonavir in HIV-1-infected pediatric patients
    Naïm Bouazza
    From the EA 3620, Universite Paris Descartes, Sorbonne Paris Cité Unité de Recherche clinique, Assistance Publique Hopitaux de Paris AP HP, Hôpital Tarnier CIC 0901 Inserm, Cochin Necker Unité d Immunologie, Hématologie et Rhumatologie pédiatriques, AP HP, Hopital Necker Enfants Malades, Paris Service de Pharmacologie Clinique, AP HP, Hopital Cochin Saint Vincent de Paul, Universite Paris Descartes, Sorbonne Paris Cité, France
    Pediatr Infect Dis J 33:e213-8. 2014
    ..0 mg/L for naive patients to compare efficacy of World Health Organization 2010 and Food and Drug Administration dosing recommendations...
  13. pmc Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics
    Elodie Valade
    EA08, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France Unité de Recherche Clinique Paris Centre, AP HP, Paris, France DHU risques et grossesse, Paris, France
    Br J Clin Pharmacol 78:1378-86. 2014
    ..The aims were to describe emtricitabine (FTC) pharmacokinetics in a large population of pregnant women during the different trimesters of pregnancy, and to explain FTC pharmacokinetic variability during pregnancy...
  14. pmc Evaluation of nevirapine dosing recommendations in HIV-infected children
    Frantz Foissac
    EA 3620 Université Paris Descartes Sorbonne Paris Cité, Unité de RechercheClinique, Hôpital Tarnier, 89 rue d Assas, Paris, France
    Br J Clin Pharmacol 76:137-44. 2013
    ..The aims of this study were to investigate the population pharmacokinetics of NVP in children, establish factors that influence NVP pharmacokinetics and evaluate the current dosing recommendations...
  15. pmc Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach
    Frantz Foissac
    EA 3620, Sorbonne Paris Cité, Universite Paris Descartes, Paris, France Unité de Recherche Clinique Paris Centre, Assistance Publique Hopitaux de Paris APHP, Paris, France
    Br J Clin Pharmacol 78:1113-21. 2014
    ....
  16. pmc Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients
    Elodie Valade
    EA 3620, Universite Paris Descartes, Sorbonne Paris Cité, Paris, France
    Antimicrob Agents Chemother 58:2256-61. 2014
    ..6 mg·h/liter). Administering 18 ml of emtricitabine oral solution (10 mg/ml) QD to patients with moderate renal impairment should yield emtricitabine exposures similar to those in patients with normal renal function...